万托林、普米克令舒、沐舒坦联合雾化吸入治疗毛细支气管炎疗效观察

目的 探讨毛细支气管炎的雾化吸入治疗方法.方法 将70例患儿随机分为两组,观察组给予万托林、普米克令舒、沐舒坦联合雾化吸入,同时静滴抗病毒药物、抗支原体药物及氢化考的松治疗;对照组给予静滴抗病毒药物、抗支原体药物及氢化考的松、氨茶碱治疗.结果 观察组和对照组患儿治疗1h后哮鸣音消失或减少的例数和呼吸困难、哮鸣音、痰鸣音消失的时间差异有显著性.结论 万托林、普米克令舒、沭舒坦联合雾化吸入治疗毛细支气管炎能够迅速改善症状、缩短病程.     

万托林、普米克令舒、沐舒坦联合雾化吸入治疗毛细支气管炎疗效观察

目的探讨毛细支气管炎的雾化吸入治疗方法。方法将70例患儿随机分为两组,观察组给予万托林、普米克令舒、沐舒坦联合雾化吸入,同时静滴抗病毒药物、抗支原体药物及氢化考的松治疗;对照组给予静滴抗病毒药物、抗支原体药物及氢化考的松、氨茶碱治疗。结果观察组和对照组患儿治疗1h后哮鸣音消失或减少的例数和呼吸困难、哮鸣音、痰鸣音消失的时间差异有显著性。结论万托林、普米克令舒、沐舒坦联合雾化吸入治疗毛细支气管炎能够迅速改善症状、缩短病程。     

普米克令舒、沐舒坦、万托林联合雾化治疗喘支的疗效观察

目的：探讨普米克令舒、沐舒坦、万托林联合雾化治疗喘支的疗效和临床意义。方法选取我院收治的患有急性喘支的患者100例,随机分为观察组和对照组。两组患者均通过止咳平喘、镇静、吸氧以及抗病毒治疗,其中观察组给予普米克令舒、沐舒坦、万托林联合雾化吸入,吸入3次/d,对照组吸入α糜蛋白酶氧气,观察两组治疗效果。结果两组患者均出现咳嗽改善、喘憋缓解、湿罗音和肺部哮鸣消失、血气分析恢复,但是观察组比对照组效果更明显,总有效率高于对照组(P<0.05),有统计学意义。结论普米克令舒、沐舒坦、万托林联合雾化治疗喘支的疗效显著,值得在临床推广使用。     

普米克令舒加可必特雾化吸入治疗小儿肺炎

目的 探讨普米克令舒加可必特通过雾化吸入治疗小儿喘息型肺炎疗效.方法 喘息性肺炎患儿160例,随机分为对照组和治疗组各80例.对照组患者采用传统的雾化方式进行治疗,治疗组采用普米克令舒联合可必特实施雾化吸入,观察疗效.结果 两组患者的治疗有效率分别为76.7％和90％,具有统计学意义(p＜0.05).结论 普米克令舒加可必特雾化吸入治疗与系统护理疗效显著.     

普米克和万托林吸入治疗小儿毛细支气管炎的临床观察

目的评价普米克和万托林联合应用治疗小儿毛细支气管炎的疗效及效益。方法将108例毛支患儿随机分为两组,治疗组为普米克和万托林联合应用,对照组单用普米克,评价治疗前后症状体征的变化。结果治疗组总有效率92.86%,对照组总有效率76.93%,治疗组疗效明显优于对照组(P<0.05)。结论万托林雾化液加普米克氧气驱动雾化吸入治疗毛细支气管炎效果好,优于单纯的普米克治疗,有较好的社会效益和经济效益。     

沐舒坦雾化吸入治疗婴幼儿毛细支气管炎60例疗效观察

毛细支气管炎是婴幼儿常见的疾病，为了探讨沐舒坦雾化吸入治疗婴幼儿毛细支气管炎的疗效；收集2001～2005年我院住院婴幼儿毛细支气管炎患者60例，现总结如下。     

甲强龙治疗毛细支气管炎的临床评价

目的 探讨甲强龙治疗毛细支气管炎的临床效果.方法 134例毛细支气管炎患者被随机分为实验组(n=69)和对照组(n=65),两组均给予基础治疗,对照组给予普米克令舒治疗方案,实验组给予甲强龙治疗方案.结果 两组在总有效率,痊愈率,PaO2,PaCO2恢复等方面军有显著性差异(P＜0.05),实验组疗效显著优于对照组.结论 甲强龙结合基础治疗应用于毛细支气管炎,能有效缓解患者症状,提高疗效,值得在临床上应用和推广.     

对沐舒坦治疗婴幼儿肺炎临床观察研究

目的：探讨沐舒坦(盐酸氨溴索)静脉推注联合压缩雾化吸入辅助治疗婴幼儿肺炎的临床疗效。方法对2013年1月~2014年1月我科收治住院的100例婴幼儿肺炎患者随机分为治疗组50例和对照组50例,两组均予以常规抗感染,口服止咳化痰药,吸氧吸痰等常规治疗方法。对于治疗组的处理是加沐舒坦15mg静脉滴注,1~2次/d。同时联合压缩雾化吸入的方法将沐舒坦针剂从气道吸入。然后,对两组的肺部湿啰音、痰鸣音的消失时间及住院天数进行比较。结果沐舒坦治疗组在治疗后肺部湿啰音、痰鸣音消失时间及住院时间比对照组短(<0.05)。从结果可以看出,治疗组的效果是远远高于对照组的,这种差异是在统计学(<0.05)的基础上科学得出的。结论沐舒坦静脉推注联合压缩雾化吸入治疗可明显提高常规抗感染治疗婴幼儿肺炎的疗效。     

普米克令舒治疗毛细支气管炎的研究进展

本文回顾了普米克令舒在临床上治疗小儿毛细支气管炎的应用。对在不同实验中使用普米克令舒的疗效进行分析。证实普米可令舒在治疗毛细支气管炎时,疗效显著。提示普米克令舒对毛细支气管炎的治疗起较重要的作用。     

普米克令舒氧驱动雾化吸入治疗婴幼儿喘憋性肺炎分析

目的：研究分析普米克令舒氧驱动雾化吸入治疗婴幼儿喘憋性肺炎临床效果。方法选取我院于2009年1月~2012年12月收治的79例婴幼儿喘憋性肺炎患者，将其随机划分为两组，对照组43例采用综合治疗方法，治疗组36例在综合治疗的基础上，采取普米克令舒氧驱动雾化吸入，对比两组患者治疗后的治疗效果。结果两组患者治疗后，治疗组36例患者治疗总有效率为94.4%，对照组43例患者治疗总有效率为86.0%，治疗组治疗总有效率优于对照组，对比有统计学意义(P<0.05)。结论在综合治疗的基础上，增加使用普米克令舒氧驱动雾化吸入治疗婴幼儿喘憋性肺炎，有效提高治疗效果，将治疗时间大大缩短，减少并发症发生率，效果显著，值得在临床治疗中推广使用。     

Level of functioning of siblings and parents of probands of varying degrees of retardation

A further analysis of already published data supports the position that retardates of low ability level less frequently have retarded siblings, retarded parents, and parents low in occupational level than do retardates higher in ability level. The analysis supports the position that there are two types of retarded individuals, persons retarded as a result of gene or chromosomal anomalies, brain injury, etc., who more frequently occur in the lower-level retardate group, and persons whose retardation represents polygenic segregation, who more frequently occur in the higher-level group.     

Modes of Inheritance of Errors of Refraction

Eighteen families in which both parents had refractions within the range of +4·0 D to −4·0 D and axial lengths seen in emmetropia (22·3-26·0 mm) showed coefficients of correlation of the order 0·5 indicative of polygenic inheritance. Such coefficients were seen for axial length (0·407) and for the cornea (0·487), but not for the lens (which is known to be yoked to the axial length). No such coefficients were seen in 19 families in which one of the parents had axial length outside the emmetropic range (nine families with long axes and 10 with short axes).

The pattern of polygenic inheritance for emmetropia (completely correlated optical components) and errors of refraction up to 4·0 D (inadequately correlated components: correlation ametropia) follows that seen in stature and other measurable characters. In contrast the high refractive errors with their abnormal axial lengths (component ametropia) are—like the extremes in stature—pathological anomalies with monofactorial inheritance.

     

Aspects of the problem of direct introduction of Standards of International Organizations

Editorial note. This article is published as part of a discussion. Particular issues of the article are disputable. First of all, this concerns the so-called “folder” method of introduction of international standards for medical devices to domestic medical practice (i.e., by direct translation of the standards and their publication as standardizing documents). Nevertheless, at least one of the problems, the problem of coordination between domestic state standards for medical devices and international recommendations of ISO and IEC, is undoubtedly of topical importance. Advancement of new health service legislation which is to be approved by law-makers will definitely introduce corrections into the present situation. The Editorial Board of Meditsinskaya Tekhnika believes this article will lessen these problems and to be welcomed by readers.